Retailing · Founded 2006 · www.medplusindia.com · BSE 543427 · NSE MEDPLUS · ISIN INE804L01022
No Notes Added Yet
Business
Medplus Health Services Ltd. is India's third-largest pharmacy retail chain based on the number of stores as of FY23. The company operates a chain of retail pharmacies primarily selling prescription and over-the-counter (OTC) medicines. Beyond pharmaceuticals, it also retails a range of other products including FMCG (Fast-Moving Consumer Goods), general merchandise, nutritional supplements, and medical devices. Its core business model revolves around offering a wide assortment of products, often at discounted prices, through its extensive network of physical stores and a growing omnichannel presence, aiming for customer convenience and loyalty. The company makes money through direct sales of these products to consumers.
Revenue Mix
Medplus primarily operates as a single business segment: pharmacy retail. The vast majority of its revenue is generated from the sale of pharmaceutical products (prescription and OTC medicines). Other segments contributing to revenue, albeit smaller, include:
FMCG & General Merchandise: Sale of daily utility items, personal care products, and other non-pharma goods.
Pathological Services: Offers basic diagnostic services through some outlets.
While specific revenue percentages for each sub-category are not publicly segmented in detail, prescription and OTC medicines form the dominant share.
Industry
The Indian pharmacy retail industry is large, growing, and historically highly fragmented, dominated by standalone pharmacies. However, it is rapidly transitioning towards organized retail and e-pharmacy models. Medplus is positioned as the third-largest organized pharmacy retailer in India by store count, behind players like Apollo Pharmacy and Reliance Retail (which includes Netmeds). It has a strong presence, particularly in South India, and is expanding into other regions. The company competes with traditional standalone pharmacies, other organized retail chains, hospital-owned pharmacies, and a growing number of online e-pharmacy platforms.
MOAT
Scale and Network Effect: With over 4,000 stores (as of recent data), Medplus benefits from a significant physical presence across various cities and towns, providing geographical reach and customer proximity. This scale can lead to better procurement terms and operational efficiencies.
Brand Recognition & Trust: An established brand over two decades has built a level of trust among its customer base, particularly in its core markets.
Operational Efficiency & Technology: Focus on robust supply chain management, inventory optimization, and technology integration (like its proprietary point-of-sale system and loyalty programs) helps manage operations across a large network.
Value Proposition: Its strategy of offering discounts and loyalty programs helps in customer retention in a price-sensitive market.
Growth Drivers
Store Network Expansion: Continued aggressive expansion into new geographical territories and deeper penetration in existing markets remains a primary growth driver.
Shift to Organized Retail: The ongoing transition from unorganized standalone pharmacies to organized retail chains provides a significant market opportunity.
Increasing Healthcare Spending: Rising disposable incomes, greater health awareness, and an aging population are contributing to higher demand for pharmaceutical and wellness products.
Omnichannel Strategy: Integration of its physical stores with its online platform (Medplus Mart app) aims to capture a larger customer base and enhance convenience.
Private Label Growth: Expansion of its private label products, which typically offer higher margins, can drive profitability and revenue growth.
Risks
Intense Competition: The Indian pharmacy retail market is highly competitive, facing strong players like Apollo Pharmacy, Reliance Retail, and numerous standalone pharmacies, as well as an increasing number of e-pharmacies, potentially leading to price wars and margin pressure.
Regulatory Changes: The pharmaceutical sector is subject to stringent regulations regarding drug pricing, licensing, and e-pharmacy operations. Any adverse changes could impact the business model or profitability.
Supply Chain and Inventory Management: Managing a vast and perishable inventory across thousands of stores requires sophisticated logistics, and any disruptions or inefficiencies can lead to losses.
Profitability Pressure from Expansion: Aggressive store expansion requires significant capital expenditure and new stores typically take time to achieve profitability, potentially impacting overall margins in the short term.
Technological Disruptions: Failure to adapt to evolving digital trends and competition from more agile e-pharmacy models could pose a risk.
Management & Ownership
Medplus was founded by Dr. Madhukar Gangadi, who serves as the Managing Director and CEO. The promoter group, led by Dr. Gangadi, holds a significant stake in the company, indicating strong alignment with business performance. The management team has extensive experience in the retail and pharmaceutical sectors, demonstrating a focus on operational efficiency, technology adoption, and expansion strategies. The ownership structure also includes institutional investors, reflecting broader market confidence.
Outlook
Medplus operates in a structural growth story within India's healthcare and retail sector, benefiting from the formalization of pharmacy retail and increasing healthcare awareness. The company's established brand, extensive store network, and focus on operational efficiency position it to capture a larger share of the growing market. However, its growth trajectory is contingent on navigating intense competition from well-capitalized rivals (both offline and online), managing the capital requirements and gestation periods for new store expansion, and adapting to potential regulatory shifts. The successful execution of its omnichannel strategy and the ability to maintain healthy margins amidst competitive pricing will be key determinants of its long-term success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1441 | 1490 | 1489 | 1576 | 1561 | 1510 | 1543 | 1679 | 1806 | 1864 |
| Other Income | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 |
| Total Income | 1451 | 1501 | 1498 | 1588 | 1574 | 1525 | 1558 | 1697 | 1824 | 1885 |
| Total Expenditure | 1350 | 1385 | 1395 | 1452 | 1429 | 1373 | 1412 | 1530 | 1648 | 1695 |
| Operating Profit | 102 | 116 | 102 | 136 | 145 | 152 | 146 | 166 | 177 | 190 |
| Interest | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 |
| Depreciation | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 |
| Provision for Tax | 6 | -2 | 3 | 9 | 11 | 10 | 10 | 13 | 15 | 16 |
| Profit After Tax | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 14 | 33 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 |
| Adjusted Earnings Per Share | 1.1 | 2.8 | 1.2 | 3.2 | 3.8 | 4.3 | 3.5 | 4.6 | 4.8 | 5.3 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1368 | 1733 | 2011 | 2132 | 2273 | 2871 | 3069 | 3779 | 4558 | 5625 | 6136 | 6892 |
| Other Income | 4 | 9 | 8 | 7 | 10 | 17 | 22 | 31 | 46 | 40 | 49 | 71 |
| Total Income | 1373 | 1742 | 2020 | 2139 | 2283 | 2888 | 3091 | 3811 | 4604 | 5665 | 6185 | 6964 |
| Total Expenditure | 1333 | 1691 | 1935 | 2073 | 2216 | 2737 | 2840 | 3490 | 4276 | 5254 | 5633 | 6285 |
| Operating Profit | 40 | 50 | 85 | 66 | 67 | 151 | 251 | 320 | 327 | 411 | 552 | 679 |
| Interest | 17 | 22 | 25 | 28 | 16 | 47 | 67 | 83 | 99 | 114 | 119 | 120 |
| Depreciation | 9 | 10 | 11 | 12 | 14 | 75 | 88 | 119 | 182 | 224 | 250 | 284 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 14 | 19 | 48 | 26 | 37 | 29 | 95 | 118 | 47 | 73 | 183 | 275 |
| Provision for Tax | 6 | 10 | 19 | -17 | 16 | 28 | 32 | 23 | -3 | 8 | 33 | 54 |
| Profit After Tax | 7 | 9 | 29 | 42 | 21 | 2 | 63 | 95 | 50 | 66 | 150 | 220 |
| Adjustments | 0 | -0 | -0 | 0 | 0 | 0 | 1 | 1 | -0 | -0 | 0 | 0 |
| Profit After Adjustments | 7 | 9 | 29 | 42 | 21 | 2 | 64 | 96 | 50 | 65 | 150 | 220 |
| Adjusted Earnings Per Share | 39.4 | 47.8 | 152.3 | 194.1 | 95.8 | 8.2 | 285.1 | 8 | 4.2 | 5.5 | 12.6 | 18.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 9% | 18% | 16% | 16% |
| Operating Profit CAGR | 34% | 20% | 30% | 30% |
| PAT CAGR | 127% | 16% | 137% | 36% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -1% | 4% | NA% | NA% |
| ROE Average | 9% | 6% | 7% | 9% |
| ROCE Average | 18% | 13% | 16% | 15% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 154 | 149 | 160 | 303 | 325 | 528 | 731 | 1418 | 1491 | 1578 | 1741 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | -1 | -1 | -1 | -1 |
| Borrowings | 62 | 65 | 54 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5 | 18 | 34 | -27 | 10 | 327 | 399 | 647 | 797 | 849 | 992 |
| Total Current Liabilities | 210 | 269 | 276 | 325 | 337 | 498 | 445 | 559 | 477 | 575 | 625 |
| Total Liabilities | 430 | 501 | 525 | 610 | 672 | 1354 | 1575 | 2624 | 2764 | 3002 | 3356 |
| Fixed Assets | 67 | 77 | 81 | 83 | 90 | 419 | 517 | 799 | 1138 | 1242 | 1296 |
| Other Non-Current Assets | 46 | 48 | 49 | 69 | 107 | 102 | 105 | 193 | 146 | 143 | 168 |
| Total Current Assets | 317 | 376 | 395 | 458 | 475 | 833 | 953 | 1632 | 1481 | 1616 | 1891 |
| Total Assets | 430 | 501 | 525 | 610 | 672 | 1354 | 1575 | 2624 | 2764 | 3002 | 3356 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 13 | 46 | 31 | 21 | 35 | -47 | 9 | -28 | -121 | 228 | 91 |
| Cash Flow from Operating Activities | -19 | -17 | 34 | 32 | 82 | -7 | 3 | 170 | 90 | 144 | 540 |
| Cash Flow from Investing Activities | -15 | -32 | -15 | -18 | -20 | -28 | -35 | -703 | 429 | -83 | -318 |
| Cash Flow from Financing Activities | 66 | 35 | -29 | -1 | -72 | 90 | -6 | 440 | -170 | -198 | -228 |
| Net Cash Inflow / Outflow | 32 | -15 | -10 | 14 | -10 | 56 | -37 | -93 | 350 | -137 | -5 |
| Closing Cash & Cash Equivalent | 45 | 31 | 21 | 35 | 24 | 9 | -28 | -121 | 228 | 91 | 86 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 39.43 | 47.84 | 152.33 | 194.06 | 95.77 | 8.22 | 285.08 | 8.03 | 4.17 | 5.48 | 12.56 |
| CEPS(Rs) | 85.43 | 100.33 | 212.89 | 251.21 | 159.72 | 350.98 | 675.81 | 17.94 | 19.42 | 24.24 | 33.42 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 716.21 | 694.75 | 752.08 | 1363.1 | 1450.49 | 2378.5 | 3044.19 | 117.89 | 122.44 | 129.47 | 143.22 |
| Core EBITDA Margin(%) | 2.61 | 2.39 | 3.81 | 2.75 | 2.5 | 4.65 | 7.32 | 7.54 | 6.08 | 6.51 | 8.09 |
| EBIT Margin(%) | 2.28 | 2.33 | 3.65 | 2.5 | 2.32 | 2.65 | 5.19 | 5.24 | 3.16 | 3.28 | 4.86 |
| Pre Tax Margin(%) | 1.01 | 1.08 | 2.38 | 1.2 | 1.61 | 1.02 | 3.04 | 3.08 | 1.02 | 1.29 | 2.95 |
| PAT Margin (%) | 0.55 | 0.52 | 1.43 | 1.99 | 0.92 | 0.06 | 2.01 | 2.47 | 1.08 | 1.15 | 2.41 |
| Cash Profit Margin (%) | 1.18 | 1.1 | 2 | 2.57 | 1.53 | 2.67 | 4.83 | 5.59 | 5.01 | 5.08 | 6.43 |
| ROA(%) | 1.73 | 1.94 | 5.62 | 7.47 | 3.26 | 0.18 | 4.31 | 4.51 | 1.86 | 2.27 | 4.73 |
| ROE(%) | 5.51 | 6.78 | 21.06 | 19.26 | 6.81 | 0.43 | 10.51 | 9.07 | 3.5 | 4.36 | 9.21 |
| ROCE(%) | 10.02 | 12.04 | 20.61 | 13.06 | 11.77 | 14.34 | 21.69 | 16.56 | 9.56 | 12.19 | 18.22 |
| Receivable days | 1.03 | 0.77 | 0.53 | 1.09 | 1.53 | 0.96 | 0.69 | 0.54 | 0.58 | 0.84 | 0.9 |
| Inventory Days | 67.6 | 59.37 | 58.51 | 59.74 | 60.81 | 65.93 | 81.18 | 79.28 | 81.27 | 79.52 | 78.76 |
| Payable days | 34.09 | 28.02 | 24.9 | 25.21 | 28.85 | 31 | 28.76 | 24.13 | 25.98 | 21.33 | 21.71 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 125.8 | 156.11 | 125.87 | 60.48 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.57 | 5.32 | 5.33 | 5.3 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.09 | 0.1 | 0.08 | 0.05 | 0.02 | -0.01 | 0.01 | 3.22 | 1.64 | 1.44 | 1.42 |
| EV/Core EBITDA(x) | 3.07 | 3.44 | 1.92 | 1.59 | 0.82 | -0.23 | 0.07 | 37.97 | 22.86 | 19.69 | 15.8 |
| Net Sales Growth(%) | 0 | 26.64 | 16.07 | 5.99 | 6.61 | 26.31 | 6.92 | 23.13 | 20.59 | 23.42 | 9.09 |
| EBIT Growth(%) | 0 | 29.35 | 81.5 | -27.21 | -1.32 | 44.56 | 113.38 | 23.63 | -27.38 | 28.24 | 61.55 |
| PAT Growth(%) | 0 | 21.32 | 218.43 | 46.9 | -50.65 | -91.42 | 3417.89 | 50.08 | -47.1 | 30.88 | 129.09 |
| EPS Growth(%) | 0 | 21.31 | 218.43 | 27.39 | -50.65 | -91.42 | 3368.17 | -97.18 | -48.06 | 31.32 | 129.29 |
| Debt/Equity(x) | 1.07 | 1.46 | 1.24 | 0.55 | 0.33 | 0.2 | 0.2 | 0.1 | 0 | 0 | 0 |
| Current Ratio(x) | 1.51 | 1.4 | 1.43 | 1.41 | 1.41 | 1.67 | 2.14 | 2.92 | 3.11 | 2.81 | 3.03 |
| Quick Ratio(x) | 0.3 | 0.25 | 0.22 | 0.29 | 0.24 | 0.38 | 0.46 | 1.28 | 0.71 | 0.48 | 0.87 |
| Interest Cover(x) | 1.79 | 1.86 | 2.89 | 1.92 | 3.27 | 1.63 | 2.41 | 2.42 | 1.48 | 1.65 | 2.54 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.45 | 40.39 | 40.39 | 40.39 | 40.39 | 40.34 | 40.32 | 40.29 | 40.29 | 40.22 |
| FII | 12.97 | 14.94 | 14.85 | 14.72 | 15.23 | 15.61 | 16.42 | 16.54 | 16.83 | 15.53 |
| DII | 25.18 | 22.47 | 22.17 | 27.97 | 25.65 | 26.19 | 26.03 | 26.52 | 26.57 | 27.82 |
| Public | 21.4 | 22.2 | 22.59 | 16.92 | 18.73 | 17.87 | 17.22 | 16.65 | 16.3 | 16.44 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 |
| FII | 1.55 | 1.79 | 1.78 | 1.76 | 1.82 | 1.87 | 1.97 | 1.98 | 2.02 | 1.86 |
| DII | 3.01 | 2.69 | 2.65 | 3.34 | 3.07 | 3.13 | 3.12 | 3.18 | 3.18 | 3.34 |
| Public | 2.55 | 2.65 | 2.7 | 2.02 | 2.24 | 2.14 | 2.06 | 2 | 1.95 | 1.97 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.94 | 11.95 | 11.95 | 11.95 | 11.95 | 11.97 | 11.97 | 11.98 | 11.98 | 12.01 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +9% | +18% | +16% | +16% |
| Operating Profit CAGR | +34% | +20% | +30% | +30% |
| PAT CAGR | +127% | +16% | +137% | +36% |
| Share Price CAGR | -1% | +4% | — | — |
| ROE Average | +9% | +6% | +7% | +9% |
| ROCE Average | +18% | +13% | +16% | +15% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.45 | 40.39 | 40.39 | 40.39 | 40.39 | 40.34 | 40.32 | 40.29 | 40.29 | 40.22 |
| FII | 12.97 | 14.94 | 14.85 | 14.72 | 15.23 | 15.61 | 16.42 | 16.54 | 16.83 | 15.53 |
| DII | 25.18 | 22.47 | 22.17 | 27.97 | 25.65 | 26.19 | 26.03 | 26.52 | 26.57 | 27.82 |
| Public | 59.55 | 59.61 | 59.61 | 59.61 | 59.61 | 59.66 | 59.68 | 59.71 | 59.71 | 59.78 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 |
| FII | 1.55 | 1.79 | 1.78 | 1.76 | 1.82 | 1.87 | 1.97 | 1.98 | 2.02 | 1.86 |
| DII | 3.01 | 2.69 | 2.65 | 3.34 | 3.07 | 3.13 | 3.12 | 3.18 | 3.18 | 3.34 |
| Public | 7.11 | 7.13 | 7.13 | 7.13 | 7.13 | 7.14 | 7.15 | 7.15 | 7.15 | 7.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.94 | 11.95 | 11.95 | 11.95 | 11.95 | 11.97 | 11.97 | 11.98 | 11.98 | 12.01 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.